Turning Point Therapeutics, a San Diego-based developer of targeted cancer drugs, is presenting updated data Friday showing that its targeted therapy helps lung cancer patients whose disease is driven by a rare genetic alteration.

The drug, repotrectinib, has been tested in 33 patients whose cancer is driven by an alteration of a gene called ROS1. Eleven of these patients have not previously been treated with another drug; of these, nine, or 82%, saw their tumors shrink by at least 30%. (Doctors call this shrinkage a “response.”)

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy